Hanx Biopharmaceuticals (Wuhan) Co., Ltd. completed an on-market buyback of 22,400 H shares on 22 June 2026. The shares were repurchased at prices ranging from HK$26.18 to HK$27.08, translating into a volume-weighted average cost of HK$26.64 per share and an aggregate consideration of HK$0.60 million.

Post-transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.017 % to 134.84 million shares, while treasury shares rose to 1.38 million. Total issued shares remain unchanged at 136.22 million.

The buyback forms part of the mandate approved on 12 February 2026, which authorises repurchases of up to 13.62 million shares. Including the latest transaction, Hanx Biopharmaceuticals has repurchased 1.38 million shares under this mandate, representing 1.01 % of the company’s issued shares at the mandate date.

All repurchased shares have been retained as treasury stock. In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 22 July 2026.